Spain fines drugmaker over €10 million for excessive pricing
Shutterstock/nito
Spain’s competition authority has become the latest enforcer to fine Leadiant Biosciences for abusing its dominance by overcharging its national health system for an orphan drug used to treat a rare metabolic disease.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Subscribe now